Targeted erythropoietin selectively stimulates red blood cell expansion in vivo
Abstract
Erythropoietin is used to treat anemia but has prothrombotic side effects that limit its use. We have demonstrated in vivo the ability to target erythropoietin to red blood cell precursors and away from platelet precursors, thereby potentially avoiding off-target effects. We have systematically determined the protein design features required for in vivo success of the engineered protein. Our results reveal how rational engineering of protein drugs can be used to reduce side effects, with broad implications for designers of therapeutic signaling systems.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 25, 2016
- Source ID
- 10.1073/pnas.1525388113
Entities
People
- Andyna Vernet
- Devin R. Burrill
- James J. Collins
- Jeffrey C Way
- Pamela Silver
Organizations
- Broad Institute
- Harvard Medical School
- Harvard University
- Massachusetts Institute of Technology
- National Heart, Lung, and Blood Institute
- National Institute of General Medical Sciences
- Wyss Institute for Biologically Inspired Engineering